Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Tergantung pada bursa, simbol saham dapat berbeda. Misalnya, di bursa , saham Clearside Biomedical diperdagangkan dengan simbol CLM0.MU.
Apakah harga saham Clearside Biomedical sedang naik?▼
Saham CLM0.MU naik +0% dibandingkan minggu sebelumnya, naik +0% selama sebulan terakhir, namun dalam setahun terakhir Clearside Biomedical menunjukkan penurunan sebesar -60%.
Berapa jumlah karyawan Clearside Biomedical?▼
Per April 30, 2026, perusahaan memiliki 32 karyawan.
Clearside Biomedical berada di sektor apa?▼
Clearside Biomedical beroperasi di sektor Kesehatan & Kebugaran.